Design and Safety Monitoring of Combination Therapies in Phase I Clinical Trials

View at publisher Summarise with VIRAT
Authors: Shesh Rai
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Phase I clinical trials represent the first step in evaluating new drugs in humans and have become increasingly complex with the growing use of combination therapies. The primary objective of Phase I trials is to identify a recommended dose that is safe, efficient, and reliable for use in subsequent phases of drug development. Although Phase I trials were historically viewed as having limited therapeutic benefit, methodological advances over the past decade have improved their ethical and clinical relevance, allowing them to serve as viable treatment options for patients. In this review, we examine major Phase I trial designs, including rule-based, model-based, and model-assisted approaches. We also discuss Phase I dose-expansion trials, which are often conducted on an ad hoc basis, and provide a theoretical justification for their use. Furthermore, we propose systematic rules for safety and toxicity monitoring in combination therapy trials, accounting for varying toxicity rates and type I error control. These considerations aim to improve the design, conduct, and interpretability of Phase I combination therapy trials.

Fields of Study & Subjects

Statistical Methods in Clinical Trials Pharmaceutical studies and practices Optimal Experimental Design Methods

Publication details

Publication date
20 March 2026
Language
EN